Low prevalence of the JAK2V617F in patients with ischemic stroke or cerebral venous thrombosis

Abstract

Quebec platelet disorder (QPD) is an autosomal dominant bleeding disorder associated with increased risks for bleeding and the expression and storage of urokinase plasminogen activator (u-PA) in platelets, despite normal u-PA in plasma (reviewed in [1]). In the recent article on QPD published in this journal [1], QPD was proposed to result from defective u-PA regulation by megakaryocytes. However, the levels of u-PA in other QPD cells and urine have not been reported. Individuals with QPD are at increased risk of experiencing bleeding following hemostatic challenges, and approximately 50% experience episodic, spontaneous hematuria, which is associated with higher levels of platelet u-PA [2]. As urine normally contains significant amounts of u-PA (40-80 mg/ml) [3], we investigated whether individuals with QPD have an increased urinary u-PA as a potential contributor to their urinary tract bleeding.

JAK2V617F mutation for the early diagnosis of Ph− myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis

“…Twenty-four studies were therefore included in this systematic review. 10,21,23,25,27,30,33,37,[40][41][42][43][44][45][46][47][48][49]51,52 Interobserver agreement for study selection was excellent ( ϭ 0.96).…”

“…Studies ranged in size from 11 to 560 patients; a total of 3508 patients were included. Six case-control studies 10,23,25,27,35,40 and 18 retrospective cohort studies 21,24,30,31,34,36,37,[41][42][43][44][45][46][47][48][49]51,52 were included in our systematic review. Five studies enrolled patients consecutively.…”

“…Five studies enrolled patients consecutively. 35,42,44,46,51 A few studies differentiated between patients with homozygote and heterozygote JAK2V617F mutation, 24,34,35,41,43,44,49 and 2 studies provided data on patients with homozygote mutation JAK2V617F. [24][25][26][27][28][29][30][31][32][33][34][35] Sixteen studies, 10,21,[23][24][25]30,[35][36][37]40,43,44,46,47,49,53 including a total 831 patients, assessed the prevalence of JAK2V617F mutation in patients with SVT.…”

Evaluation on Thrombotic Events Frequency in JAK2 V617F Positive Patients

“…With this data, we emphasize the role of the research about this mutation on the investigation about the causes of thrombotic events especially in unusual site highlighting the MPN as a cause of thrombophilia. This probably occurs due to correlation of the mutation presence and the increase of platelets and leukocytes and with the hypercoagulable state [3].…”

“…Besides this studies suggest that these patients with MPN who have the JAK2 V617Fmutation are exposed to an increasing risk of thrombotic complications possibly because of the increased platelet and the leukocyte activation [3].…”